Driven to improve patients’ lives, Byondis is an independent, fully integrated biopharmaceutical research and development company creating innovative targeted medicines for cancer. The company is developing new biological entities (NBEs) with a focus on antibody-drug conjugates. Byondis’ development portfolio leverages its expertise in linker-drug (LD) technology, antibody-drug conjugation and disease biology. Byondis’ fully integrated drug development capabilities cover all stages from pre-clinical and clinical R&D, production of clinical batches of the selected product candidates and regulatory filings, which are all done in-house. The company has a dedicated team of more than 200 staff working in its state-of-the-art R&D and GMP manufacturing facilities in Nijmegen, the Netherlands.
| Website | https://www.byondis.com |
| Revenue | $49.7 million |
| Employees | 232 (190 on RocketReach) |
| Founded | 2012 |
| Address | 4 Microweg, Nijmegen, Gelderland 6503 GB, NL |
| Phone | +31 24 679 5100 |
| Industry | Pharmaceutical Manufacturing, Manufacturing General, Manufacturing |
| Keywords | Immuno Oncology, Precision Medicine, Cancer Treatment, Autoimmune Disease Treatment, Targeted Therapy, Biotechnology, Pharmaceutical, Drug Development, Clinical Trials, Novel Therapeutics, Therapeutic Antibodies, Biopharma, Oncology Therapeutics, Immunotherapy, Drug Discovery, Biologics, Medicine, Healthcare |
| Competitors | Genmab, Roche, AstraZeneca, Amgen, Regeneron, Gilead Sciences, Bristol Myers Squibb, Sanofi, Lilly India, Pfizer +46 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 32 Companies, NAICS Code 325 Companies |
Looking for a particular Byondis employee's phone or email?
The Byondis annual revenue was $49.7 million in 2026.
Marieke van Gent is the Vice President Intellectual Property of Byondis.
190 people are employed at Byondis.
Byondis is based in Nijmegen, Gelderland.
The NAICS codes for Byondis are [32, 325].
The SIC codes for Byondis are [283, 28].